Medicus Pharma Ltd. MDCX said Monday it has submitted an optimized Phase 2 study design to the U.S. Food and Drug ...
To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10373/251904_9ea3c480f4166aa2_001full.jpg "My family has a history of ...
Hosted on MSN
Profound Medical Completes First Commercial BPH Treatment With New TULSA-AI Volume Reduction Module
Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...
MIAMI, FLORIDA / ACCESS Newswire / November 25, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), a preclinical-stage biotechnology company developing therapies that ...
A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of ...
SALT LAKE CITY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced the integration of Absolute Risk ...
Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...
Non-cancer causes of death in patients with hormone-sensitive prostate cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary Cancers Symposium. This abstract does not include a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results